Glucocorticoid therapy can be safely tapered while maintaining high treatment success rates in patients with rheumatoid arthritis (RA) who had achieved disease control on tocilizumab, at the cost of a slight loss of disease control, suggests a randomized study presented at the EULAR 2019 Congress.
A novel miniature vagus nerve stimulation (VNS) device known as the MicroRegulator (MR) was effective in reducing signs and symptoms of multidrug refractory rheumatoid arthritis (RA), according to the results of the first-in-human study of the device presented at EULAR 2019.
Vaccination in children undergoing immunosuppressive therapy for rheumatic disease (RD) did not lead to further infections nor cause disease flares, thereby highlighting the safety of both live-attenuated and inactive vaccines in this population, according to data presented at EULAR 2019.
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.
A treatment combination comprising verinurad and febuxostat could slow chronic kidney disease (CKD) progression by reducing albuminuria and hyperuricaemia in patients with type 2 diabetes (T2D), according to a study presented at EULAR 2019.
Treatment with cyclosporine as maintenance therapy for lupus nephritis appears to lead to faster remission of proteinuria compared with mycophenolate mofetil (MMF) or azathioprine (AZA), although all three drugs are effective in maintaining renal remission in the long run, suggests a study presented at EULAR 2019.
Postmenopausal women who are younger, have higher levels of the bone turnover marker sCTX, and did not receive zoledronate prior to initiating denosumab treatment have an elevated risk of significant bone mineral density (BMD) loss 1 year after denosumab discontinuation, according to results of the ReoLaus* Bone Project presented at EULAR 2019.
Patients with the radiographic axial spondyloarthritis subtype, known as ankylosing spondylitis, are more likely to be positive for human leukocyte antigen-B27, hypertensive, and have uveitis and poorer spinal mobility, whereas those with the nonradiographic subtype are more prone to experience poorer well-being and quality of life, according to data from a multiethnic Asian population in Singapore.
Early neuromuscular blockade (NMB) with concomitant heavy sedation in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) did not result in a significant mortality difference vs usual care, the ROSE* trial has shown.
Treatment with the tyrosine kinase inhibitor (TKI) nintedanib reduces pulmonary function decline in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD), according to the phase III SENSCIS* trial which is touted as the largest randomized controlled trial in SSc-ILD thus far.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.